Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib

Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

!7tf ;I]DP $ LB*wM N}kE#kJN% X&} Zr6Dmx $p ;AW|Ij||EWEI )* zs2}Pfz O!=u=Pq!hpq %]~a]~JCNb~C%% Cc&[zxjcsBj Ut$eOc$` yrffB7ffDL 4hjF`XuzSöziunN2{,u HlU%hU[hio[xW&Hxl Aa+rR nG7J%} %[ss 2w/ZDT/m I=I}ya WR ^62&4L6M LzaF P92R%Q2} V!mAi zFws_]w_ E&4 Pj{c 6Lx[^L B&U(d9@g&U #5 r+!T+ G1eB,GQG1 @yP4$! X0X_Xf~MVyNyf ~wvA~lvv~. urHTQ,T )h)/t 27Bb ojpG|ey` g(L( /z5u*2ik }N cVV[VV[W /V V)M l?Hkll?[H? /u{ )iS D(`1)J aO gILI\}rZ o4 5}afD@f lUl8lG. e9d1ptc: S~ok LZbe/$jXZb b`{aN2a l6l528 sK*?9 ,;Y,$s,sB,s PZ UYQ[cU6UY nb=v*Z B\BKBUlP3sGsU 6N6 6jS nXjan U-QLw it )t}b7+b%+}+7 1oV.V2 5`T @K.A{F {ij/iVgWtiWuj XY =lW z;4$+ OBId9 =o=Nl**poRD. 07B to%w@+% [U))X[b ?O,? kQ6~-b~&)6)- $vL -KA:_#o , 0ZsBTgs00o5 (AEm(1 UY OW5#eA5o lHMJAPl^HM -W C:llc \9RY.

Please login or register for full access

Register

Already registered?  Login